Abstract
Purpose :
To evaluate visual acuity after treatment of diabetic macular edema from patients stratified randomly into two groups in which one received ranibizumab and one received aflibercept.
Methods :
This is a randomized clinical trial of patients treated in retina sector of Goiânia Institute of Eyes. Patients were diagnosed with non-proliferative or proliferative diabetic retinopathy associated with clinically significant diabetic macular edema justifying treatment with anti-VEGF. These were stratified into two groups in a randomized manner, in which one received alibercept 0.05 ml and the other ranibizumab 0.05 ml and subsequent visual acuity assessment being subjected to descriptive statistical analysis related to improvement, stability or worsening of visual acuity after the application of these different medications at days five and thirty after treatment.
Results :
Eighteen eyes of 16 patients diagnosed with diabetic retinopathy in which there were no other diseases that justified the appearance of macular edema were evaluated. Among the selected 9 were male and 7 female. With the evaluation through the stratification already cited in the methodology after the fifth day of application of aflibercept, an improvement in visual acuity of about one line was already observed on the Snellen table, which increased to two lines in the evaluation of the thirtieth day Post intravitreal application; In the group receiving ranibizumab an improvement in visual acuity was observed for about a line that remained until the thirtieth day after application.
Conclusions :
Compared with data in the literature, it was observed that aflibercept, besides having a longer lasting effect related to the reduction of diabetic macular edema according to studies related to optical coherence tomography, was also more efficient in the partial and long-term recovery of acuity Visual evaluation of the evaluated patients.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.